Compare Stocks: AVTE, PHVS, PVLA, and MESO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTE Aerovate Therapeutics	$17.89 -6.5%	$21.15	$89.95 ▼ $99.05	$518.54M	0.95	53,591 shs	1.25 million shs
MESO Mesoblast	$15.48 -0.1%	$16.17	$13.05 ▼ $21.50	$2.01B	2.12	196,961 shs	180,172 shs
PHVS Pharvaris	$38.02 +1.4%	$35.09	$20.65 ▼ $43.25	$2.49B	-2.33	932,745 shs	1.45 million shs
PVLA Palvella Therapeutics	$150.13 -0.2%	$148.79	$53.30 ▼ $161.38	$2.16B	-0.25	182,149 shs	163,345 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTE Aerovate Therapeutics	-6.53%	-10.10%	-22.92%	+16.62%	+134.78%
MESO Mesoblast	0.00%	-10.62%	-6.12%	+11.13%	-0.51%
PHVS Pharvaris	0.00%	+7.86%	+11.69%	+23.76%	+63.53%
PVLA Palvella Therapeutics	0.00%	-4.52%	-4.10%	+37.97%	+151.35%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTE Aerovate Therapeutics	$17.89 -6.5%	$21.15	$89.95 ▼ $99.05	$518.54M	0.95	53,591 shs	1.25 million shs
MESO Mesoblast	$15.48 -0.1%	$16.17	$13.05 ▼ $21.50	$2.01B	2.12	196,961 shs	180,172 shs
PHVS Pharvaris	$38.02 +1.4%	$35.09	$20.65 ▼ $43.25	$2.49B	-2.33	932,745 shs	1.45 million shs
PVLA Palvella Therapeutics	$150.13 -0.2%	$148.79	$53.30 ▼ $161.38	$2.16B	-0.25	182,149 shs	163,345 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTE Aerovate Therapeutics	-6.53%	-10.10%	-22.92%	+16.62%	+134.78%
MESO Mesoblast	0.00%	-10.62%	-6.12%	+11.13%	-0.51%
PHVS Pharvaris	0.00%	+7.86%	+11.69%	+23.76%	+63.53%
PVLA Palvella Therapeutics	0.00%	-4.52%	-4.10%	+37.97%	+151.35%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTE Aerovate Therapeutics	0.00	N/A	N/A	N/A
MESO Mesoblast	2.00	Hold	$39.00	151.94% Upside
PHVS Pharvaris	2.79	Moderate Buy	$59.50	56.50% Upside
PVLA Palvella Therapeutics	3.00	Buy	$209.14	39.31% Upside

Current Analyst Ratings Breakdown

Latest AVTE, PHVS, PVLA, and MESO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/10/2026	PHVS Pharvaris	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$40.00 ➝ $44.00
9/9/2026	PHVS Pharvaris	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$42.00 ➝ $50.00
9/9/2026	PHVS Pharvaris	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$50.00 ➝ $65.00
9/9/2026	PHVS Pharvaris	Rosenblatt Securities Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$60.00
9/9/2026	PHVS Pharvaris	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$46.00 ➝ $62.00
9/9/2026	PHVS Pharvaris	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$79.00
9/9/2026	PHVS Pharvaris	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$55.00 ➝ $65.00
9/9/2026	PHVS Pharvaris	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/9/2026	PHVS Pharvaris	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$52.00 ➝ $62.00
9/9/2026	PHVS Pharvaris	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Outperform	$75.00 ➝ $79.00
8/27/2026	MESO Mesoblast	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$35.00 ➝ $39.00

(Data available from 9/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	$3.96 per share	N/A
MESO Mesoblast	$120.25M	16.72	N/A	N/A	$4.38 per share	3.53
PHVS Pharvaris	N/A	N/A	N/A	N/A	$4.71 per share	N/A
PVLA Palvella Therapeutics	$42.81M	50.53	N/A	N/A	$2.36 per share	63.61

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTE Aerovate Therapeutics	-$75.52M	-$1.70	N/A	N/A	N/A	N/A	-90.19%	-77.47%	N/A
MESO Mesoblast	-$57.50M	-$0.28	N/A	43.00	N/A	N/A	N/A	N/A	N/A
PHVS Pharvaris	-$198.79M	-$3.05	N/A	N/A	N/A	N/A	-61.40%	-56.00%	11/11/2026 (Estimated)
PVLA Palvella Therapeutics	-$41.72M	-$4.83	N/A	N/A	N/A	N/A	-47.84%	-38.33%	11/10/2026 (Estimated)

Latest AVTE, PHVS, PVLA, and MESO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	PHVS Pharvaris	-$0.7467	-$0.81	-$0.0633	-$0.80	N/A	N/A
8/4/2026	Q2 2026	PVLA Palvella Therapeutics	-$1.17	-$1.52	-$0.35	-$1.52	N/A	N/A
7/31/2026	Q4 2026	MESO Mesoblast	N/A	-$0.0660	N/A	-$0.0660	N/A	$34.45 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	N/A	N/A	N/A	N/A	N/A
PHVS Pharvaris	N/A	N/A	N/A	N/A	N/A
PVLA Palvella Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTE Aerovate Therapeutics	N/A	8.78	8.78
MESO Mesoblast	0.19	2.43	2.09
PHVS Pharvaris	N/A	11.94	11.94
PVLA Palvella Therapeutics	N/A	21.18	21.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVTE Aerovate Therapeutics	N/A
MESO Mesoblast	1.43%
PHVS Pharvaris	N/A
PVLA Palvella Therapeutics	40.11%

Insider Ownership

Company	Insider Ownership
AVTE Aerovate Therapeutics	24.90%
MESO Mesoblast	18.80%
PHVS Pharvaris	11.84%
PVLA Palvella Therapeutics	17.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTE Aerovate Therapeutics	20	28.99 million	21.69 million	Optionable
MESO Mesoblast	108	129.88 million	105.46 million	Optionable
PHVS Pharvaris	148	65.41 million	57.66 million	Not Optionable
PVLA Palvella Therapeutics	29	14.41 million	11.93 million	N/A

AVTE, PHVS, PVLA, and MESO Headlines

Recent News About These Companies

50,001 Shares in Palvella Therapeutics, Inc. $PVLA Purchased by Hsbc Holdings PLC

September 10 at 4:47 AM | marketbeat.com

Palvella Therapeutics, Inc. $PVLA Stock Holdings Decreased by First Light Asset Management LLC

September 10 at 4:31 AM | marketbeat.com

Palvella Therapeutics Inc.: Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer

September 9, 2026 | finanznachrichten.de

Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer

September 9, 2026 | finance.yahoo.com

Palvella Therapeutics Appoints James Treat, M.D., as Chief Medical Officer

September 9, 2026 | quiverquant.comQ

Palvella Therapeutics Appoints James R. Treat, M.D.

September 9, 2026 | globenewswire.com

Legal & General Group Plc Purchases Shares of 7,994 Palvella Therapeutics, Inc. $PVLA

September 7, 2026 | marketbeat.com

Bank of New York Mellon Corp Invests $4.67 Million in Palvella Therapeutics, Inc. $PVLA

September 6, 2026 | marketbeat.com

Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Average Rating of "Buy" by Brokerages

September 6, 2026 | americanbankingnews.com

Christopher Kiritsy Sells 313 Shares of Palvella Therapeutics (NASDAQ:PVLA) Stock

September 5, 2026 | insidertrades.com

Insider Selling: Palvella Therapeutics (NASDAQ:PVLA) Director Sells $49,141.00 in Stock

September 4, 2026 | marketbeat.com

The Manufacturers Life Insurance Company Takes Position in Palvella Therapeutics, Inc. $PVLA

September 3, 2026 | marketbeat.com

Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences

September 2, 2026 | globenewswire.com

Alyeska Investment Group L.P. Lowers Stake in Palvella Therapeutics, Inc. $PVLA

September 2, 2026 | marketbeat.com

Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Average Rating of "Buy" by Analysts

September 1, 2026 | marketbeat.com

Palvella Therapeutics, Inc. $PVLA Shares Sold by Montanova Capital LLC

September 1, 2026 | marketbeat.com

Palvella Therapeutics Completes Rolling Submission of NDA for QTORIN Rapamycin

August 31, 2026 | finance.yahoo.com

Palvella Completes Rolling NDA For QTORIN Rapamycin In Microcystic Lymphatic Malformatios

August 31, 2026 | rttnews.com

Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

August 31, 2026 | globenewswire.com

Hsbc Holdings PLC Invests $7.64 Million in Palvella Therapeutics, Inc. $PVLA

August 29, 2026 | marketbeat.com

Deutsche Bank AG Invests $1.81 Million in Palvella Therapeutics, Inc. $PVLA

August 29, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AVTE, PHVS, PVLA, and MESO Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

$17.89 -1.25 (-6.53%)

As of 09/11/2026

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Mesoblast NASDAQ:MESO

$15.48 -0.02 (-0.13%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$15.49 +0.01 (+0.06%)

As of 09/11/2026 07:30 PM Eastern

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Pharvaris NASDAQ:PHVS

$38.02 +0.51 (+1.36%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$38.36 +0.34 (+0.89%)

As of 09/11/2026 07:30 PM Eastern

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

Palvella Therapeutics NASDAQ:PVLA

$150.13 -0.26 (-0.17%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$150.26 +0.13 (+0.08%)

As of 09/11/2026 07:30 PM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AVTE, PHVS, PVLA, and MESO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AVTE, PHVS, PVLA, and MESO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AVTE, PHVS, PVLA, and MESO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AVTE, PHVS, PVLA, and MESO Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

Mesoblast NASDAQ:MESO

Pharvaris NASDAQ:PHVS

Palvella Therapeutics NASDAQ:PVLA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AVTE, PHVS, PVLA, and MESO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AVTE, PHVS, PVLA, and MESO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AVTE, PHVS, PVLA, and MESO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AVTE, PHVS, PVLA, and MESO Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

Mesoblast NASDAQ:MESO

Pharvaris NASDAQ:PHVS

Palvella Therapeutics NASDAQ:PVLA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools